Zimmer Biomet has named Dr. Jonathan M. Vigdorchik as its new Chief Science, Technology and Medical Affairs Officer, effective April 14, 2026. Dr. Vigdorchik, an experienced orthopedic surgeon and former Chief Medical Technology Advisor, will lead the company's global technology portfolio including AI, robotics, and smart implants. His role also includes overseeing medical education and strengthening clinical innovation. This appointment aims to accelerate Zimmer Biomet's innovation and market differentiation in musculoskeletal care.
Zimmer Biomet has appointed Chintan Desai as president of its Asia Pacific region, effective immediately. Desai brings nearly 30 years of leadership experience in the medical technology sector, including senior roles at Alcon and GE Healthcare. He re...
Zimmer Biomet Holdings announced its second quarter 2026 earnings conference call will be held on August 5 at 8:30 a.m. ET, with a news release detailing results available earlier that day. The call will be webcast live and available for replay on th...
The AI in orthopedic surgery market is projected to grow from $0.26 billion in 2025 to $0.87 billion by 2030, at a CAGR of 27.2%. Growth is fueled by increased orthopedic surgeries, innovations in medical imaging, adoption of minimally invasive techn...
